Group 1 - The Hong Kong innovative drug sector is active, with the Hang Seng Innovative Drug Index rising by 0.7% as of 9:50 AM [1] - The Hang Seng Innovative Drug ETF (159316) has seen over 100 million yuan in net inflows over the past 10 trading days, reaching a record size of 570 million yuan [1] - The adjustment of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalogues has officially started, focusing on innovative drugs with high clinical value that cannot be included in the basic catalogue [1] Group 2 - Goldman Sachs notes that the overall market capitalization of Chinese biotech companies is only 14%-15% of their US counterparts, despite contributing nearly 33% to global innovation [1] - The Hang Seng Innovative Drug Index has announced a revision to its compilation scheme, excluding CXO companies, making it the first index with 100% purity for innovative drugs [1] - The Hang Seng Innovative Drug ETF (159316) is the only ETF tracking this revised index, facilitating investor access to industry leaders [1]
我国首次新增商保创新药目录，恒生创新药ETF（159316）规模创历史新高
Mei Ri Jing Ji Xin Wen·2025-07-15 02:48